Literature DB >> 20577264

Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery.

X Shawn Liu1, Hongchang Li, Bing Song, Xiaoqi Liu.   

Abstract

In response to G2 DNA damage, the p53 pathway is activated to lead to cell-cycle arrest, but how p53 is eliminated during the subsequent recovery process is poorly understood. It has been established that Polo-like kinase 1 (Plk1) controls G2 DNA-damage recovery. However, whether Plk1 activity contributes to p53 inactivation during this process is unknown. In this study, we show that G2 and S-phase-expressed 1 (GTSE1) protein, a negative regulator of p53, is required for G2 checkpoint recovery and that Plk1 phosphorylation of GTSE1 at Ser 435 promotes its nuclear localization, and thus shuttles p53 out of the nucleus to lead to its degradation during the recovery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20577264      PMCID: PMC2920445          DOI: 10.1038/embor.2010.90

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  13 in total

Review 1.  Checking out the G(2)/M transition.

Authors:  V A Smits; R H Medema
Journal:  Biochim Biophys Acta       Date:  2001-05-28

2.  Cell-cycle regulation of the p53-inducible gene B99.

Authors:  L Collavin; M Monte; R Verardo; C Pfleger; C Schneider
Journal:  FEBS Lett       Date:  2000-09-08       Impact factor: 4.124

3.  hGTSE-1 expression stimulates cytoplasmic localization of p53.

Authors:  Martin Monte; Roberta Benetti; Licio Collavin; Luigi Marchionni; Giannino Del Sal; Claudio Schneider
Journal:  J Biol Chem       Date:  2004-01-05       Impact factor: 5.157

4.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage.

Authors:  F Bunz; A Dutriaux; C Lengauer; T Waldman; S Zhou; J P Brown; J M Sedivy; K W Kinzler; B Vogelstein
Journal:  Science       Date:  1998-11-20       Impact factor: 47.728

5.  A novel p53-inducible gene coding for a microtubule-localized protein with G2-phase-specific expression.

Authors:  R Utrera; L Collavin; D Lazarević; D Delia; C Schneider
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

Review 6.  Regulation of the G2/M transition by p53.

Authors:  W R Taylor; G R Stark
Journal:  Oncogene       Date:  2001-04-05       Impact factor: 9.867

7.  Polo-like kinase-1 is a target of the DNA damage checkpoint.

Authors:  V A Smits; R Klompmaker; L Arnaud; G Rijksen; E A Nigg; R H Medema
Journal:  Nat Cell Biol       Date:  2000-09       Impact factor: 28.824

8.  Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells.

Authors:  Marcel A T M van Vugt; Alexandra Brás; René H Medema
Journal:  Mol Cell       Date:  2004-09-10       Impact factor: 17.970

9.  Wip1 confers G2 checkpoint recovery competence by counteracting p53-dependent transcriptional repression.

Authors:  Arne Lindqvist; Menno de Bruijn; Libor Macurek; Alexandra Brás; Anneloes Mensinga; Wytse Bruinsma; Olaf Voets; Onno Kranenburg; René H Medema
Journal:  EMBO J       Date:  2009-08-27       Impact factor: 11.598

10.  The cell cycle-regulated protein human GTSE-1 controls DNA damage-induced apoptosis by affecting p53 function.

Authors:  Martin Monte; Roberta Benetti; Giacomo Buscemi; Peter Sandy; Giannino Del Sal; Claudio Schneider
Journal:  J Biol Chem       Date:  2003-05-15       Impact factor: 5.157

View more
  52 in total

1.  Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer.

Authors:  Long Chen; Nihal Ahmad; Xiaoqi Liu
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 2.  Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development.

Authors:  Jijing Luo; Xiaoqi Liu
Journal:  Protein Cell       Date:  2012-03-23       Impact factor: 14.870

3.  Polo-like kinase 1 activated by the hepatitis B virus X protein attenuates both the DNA damage checkpoint and DNA repair resulting in partial polyploidy.

Authors:  Leo Studach; Wen-Horng Wang; Gregory Weber; Jiabin Tang; Ronald L Hullinger; Raphael Malbrue; Xiaoqi Liu; Ourania Andrisani
Journal:  J Biol Chem       Date:  2010-07-12       Impact factor: 5.157

4.  Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.

Authors:  Zhe Zhang; Xianzeng Hou; Chen Shao; Junjie Li; Ji-Xin Cheng; Shihuan Kuang; Nihal Ahmad; Timothy Ratliff; Xiaoqi Liu
Journal:  Cancer Res       Date:  2014-09-24       Impact factor: 12.701

5.  Plk1 phosphorylation of Orc2 promotes DNA replication under conditions of stress.

Authors:  Bing Song; X Shawn Liu; Korbin Davis; Xiaoqi Liu
Journal:  Mol Cell Biol       Date:  2011-09-26       Impact factor: 4.272

6.  Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.

Authors:  Jie Li; Ruixin Wang; Yifan Kong; Meaghan M Broman; Colin Carlock; Long Chen; Zhiguo Li; Elia Farah; Timothy L Ratliff; Xiaoqi Liu
Journal:  Mol Cancer Ther       Date:  2017-01-09       Impact factor: 6.261

7.  Low-dose arsenic-mediated metabolic shift is associated with activation of Polo-like kinase 1 (Plk1).

Authors:  Zhiguo Li; Ying Lu; Nihal Ahmad; Klaus Strebhardt; Xiaoqi Liu
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

8.  Plk1 Phosphorylation of Mre11 Antagonizes the DNA Damage Response.

Authors:  Zhiguo Li; Jie Li; Yifan Kong; Shan Yan; Nihal Ahmad; Xiaoqi Liu
Journal:  Cancer Res       Date:  2017-05-16       Impact factor: 12.701

9.  Plk1-Mediated Phosphorylation of TSC1 Enhances the Efficacy of Rapamycin.

Authors:  Zhiguo Li; Yifan Kong; Longzhen Song; Qian Luo; Jinghui Liu; Chen Shao; Xianzeng Hou; Xiaoqi Liu
Journal:  Cancer Res       Date:  2018-03-20       Impact factor: 12.701

10.  Polo-like kinase 1 (Plk1) overexpression enhances ionizing radiation-induced cancer formation in mice.

Authors:  Zhiguo Li; Jinghui Liu; Jie Li; Yifan Kong; George Sandusky; Xi Rao; Yunlong Liu; Jun Wan; Xiaoqi Liu
Journal:  J Biol Chem       Date:  2017-09-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.